Evidence map›Paper›PMID 19609579›Full record

ArticleJournal of molecular modeling2010

3D-QSAR study of c-Src kinase inhibitors based on docking.

Ran Cao, Na Mi, Huabei Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ran CaoKey Laboratory of radiopharmaceuticals of Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China.
Na Mi
Huabei Zhang
Beijing Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a significant world health problem for which efficient therapies are in urgent demand. c-Src has emerged as an attractive target for drug discovery efforts toward antitumor therapies. Toward this target several series of c-Src inhibitors that showed activity in the assay have been reported. In this article, 3D-QSAR models have been built with 156 anilinoquinazoline and quinolinecarbonitrile derivative inhibitors by using CoMFA and CoMSIA methods. These studies indicated that the QSAR models were statistically significant with high predictabilities (CoMFA model, q(2) = 0.590, r(2) = 0.855; CoMSIA model, q(2) = 0.538, r(2) = 0.748). The details of c-Src kinase/inhibitor binding interactions in the crystal structure of complex provided new information for the design of new inhibitors. As a result, docking simulations were also conducted on the series of potent inhibitors. The flexible docking method, which was performed by the DOCK program, positioned all of the inhibitors into the active site to determine the probable binding conformation. The CoMFA and CoMSIA models based on the flexible docking conformations also yielded statistically significant and highly predictive QSAR models (CoMFA model, q(2) = 0.507, r(2) = 0.695; CoMSIA model, q(2) = 0.463, r(2) = 0.734). Our models would offer help to better comprehend the structure-activity relationships that exist for this class of compounds and also facilitate the design of novel inhibitors with good chemical diversity.

Indexed as

Antineoplastic AgentsComputer SimulationCSK Tyrosine-Protein KinaseHumansNitrilesProtein BindingProtein Kinase InhibitorsProtein-Tyrosine KinasesQuantitative Structure-Activity RelationshipQuinazolinesQuinolinessrc-Family KinasesAntineoplastic AgentsCSK protein, humanCSK Tyrosine-Protein KinaseNitrilesProtein Kinase InhibitorsProtein-Tyrosine KinasesQuinazolinesquinolineQuinolinessrc-Family Kinases

Identifiers

PMID19609579
OpenAlexW4249282225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.